FIELD: biotechnology.
SUBSTANCE: use of an antibody against adrenomedullin (hereinafter – ADM), or a fragment of an antibody against adrenomedullin, or an anti-ADM non-Ig frame is presented, where the specified antibody against ADM, or the fragment of the antibody against ADM, or the anti-ADM non-Ig frame binds with N-end part.
EFFECT: invention is effectively used in the therapy of hyperemia in a patient.
10 cl, 21 dwg, 11 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DPP3 FOR IMPLEMENTATION, MONITORING AND STRATIFICATION OF THERAPY WITH NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK | 2021 |
|
RU2838370C1 |
| COMPOUND BINDING ADRENOMEDULLIN (ADM) FOR USE FOR THERAPY OR PREVENTION OF DISEASE SYMPTOMS | 2018 |
|
RU2790561C2 |
| THERAPY MONITORING IN TREATMENT WITH BINDING AGENT AGAINST ADRENOMEDULLIN (ADM) | 2018 |
|
RU2776811C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| ANTI-IGE ANTIBODIES | 2017 |
|
RU2816207C2 |
| ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
